Hyperadiponectinemia in AD is expected to be a compensatory response to the lower efficiency of the insulin/insulin-like growth factor 1 (IGF-1) receptor signaling cascade during neurodegeneration (Waragai et al., 2017). This evidence concerns the gene INS and Alzheimer disease.